{"denoms":[{"counts":[{"groupId":"BG000","value":"699"},{"groupId":"BG001","value":"702"},{"groupId":"BG002","value":"1401"}],"units":"Participants"}],"groups":[{"description":"Participants received either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during induction period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"BG000","title":"Rituximab+Chemotherapy - Induction Period"},{"description":"Participants received either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"BG001","title":"Obinutuzumab+Chemotherapy - Induction Period"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.3","value":"58.1"},{"groupId":"BG001","spread":"11.6","value":"58.9"},{"groupId":"BG002","spread":"11.9","value":"58.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"699"},{"groupId":"BG001","value":"702"},{"groupId":"BG002","value":"1401"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"374"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"739"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"325"},{"groupId":"BG001","value":"337"},{"groupId":"BG002","value":"662"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"699"},{"groupId":"BG001","value":"702"},{"groupId":"BG002","value":"1401"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.2","value":"57.7"},{"groupId":"BG001","spread":"11.5","value":"58.2"},{"groupId":"BG002","spread":"11.9","value":"57.9"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"699"},{"groupId":"BG001","value":"702"},{"groupId":"BG002","value":"1401"}],"units":"Participants"}]}],"description":"Age continuous for participants with follicular lymphoma (FL) in each arm, who encompassed the population for the primary outcome measure. The FL ITT included participants in the ITT population with follicular histology (n=601 in each arm).","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous in Follicular Lymphoma Sub-Population","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"321"},{"groupId":"BG001","value":"318"},{"groupId":"BG002","value":"639"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"280"},{"groupId":"BG001","value":"283"},{"groupId":"BG002","value":"563"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"601"},{"groupId":"BG001","value":"601"},{"groupId":"BG002","value":"1202"}],"units":"Participants"}]}],"description":"Gender of participants with follicular lymphoma, who encompassed the population for the primary outcome measure. The FL ITT included participants in the ITT population with follicular histology (n=601 for each arm).","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"As this is a sub-population, the numbers analyzed differ from the overall population numbers as not all are included here.","title":"Gender in Follicular Lymphoma Sub-Population","unitOfMeasure":"Participants"}],"populationDescription":"The intent-to treat (ITT) population was defined as all randomized participants grouped according to their randomized treatment arm regardless of what treatments were actually received."}